MFG
ALDX icon

Merit Financial Group’s Aldeyra Therapeutics ALDX Stock Holding History

Merit Financial Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.5K Sell
16,664
-3,015
-15% -$5.18K ﹤0.01% 2315
2026
Q1 		$33.3K Buy
+19,679
New +$86.2K ﹤0.01% 2077

Other funds holding ALDX

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Merit Financial Group's ALDX Position: Q2 2026 in Review

Merit Financial Group reduced its Aldeyra Therapeutics (ALDX) stake by 15% in Q2 2026, selling an estimated $5.18K and leaving 16,664 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2315.

Merit Financial Group first reported a position in ALDX in Q1 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Merit Financial Group held 16,664 shares of Aldeyra Therapeutics worth $35.5K as of Q2 2026.
  • Merit Financial Group sold 3,015 Aldeyra Therapeutics shares in Q2 2026, an estimated $5.18K.
  • Aldeyra Therapeutics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2315 holding.
  • Merit Financial Group first reported a position in Aldeyra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.